These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12052005)

  • 21. Science and transscience in carcinogen risk assessment--the European Union regulatory process for trichloroethylene.
    Rudén C
    J Toxicol Environ Health B Crit Rev; 2003; 6(3):257-77. PubMed ID: 12746141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk assessment policy in the United States.
    Flamm WG
    Prog Clin Biol Res; 1986; 208():141-9. PubMed ID: 3960883
    [No Abstract]   [Full Text] [Related]  

  • 23. Extrapolations are the Achilles heel of risk assessment.
    Preston RJ
    Mutat Res; 2005 May; 589(3):153-7. PubMed ID: 15878140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reproductive toxicants have a threshold of adversity.
    Piersma AH; Hernandez LG; van Benthem J; Muller JJ; van Leeuwen FX; Vermeire TG; van Raaij MT
    Crit Rev Toxicol; 2011 Jul; 41(6):545-54. PubMed ID: 21609253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The risk assessment of cancer morbidity in the joint action of carcinogens].
    Shaĭkina OI; Shaĭkin AB; Kon'shina LG
    Gig Sanit; 1999; (1):41-3. PubMed ID: 10199078
    [No Abstract]   [Full Text] [Related]  

  • 26. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding population and individual risk assessment: the case of polychlorinated biphenyls.
    Shields PG
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):830-9. PubMed ID: 16702358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Product safety, risk assessment, and responsible care in the biocide chemical industry.
    Weiler ED; Jayjock MA; Levy HC
    Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 1):1-5. PubMed ID: 8921539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of various methodologies with respect to specificity and sensitivity in biomonitoring occupational exposure to mutagens and carcinogens.
    Lohman PH; Jansen JD; Baan RA
    IARC Sci Publ; 1984; (59):259-77. PubMed ID: 6545282
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
    Eichenbaum G; Johnson M; Kirkland D; O'Neill P; Stellar S; Bielawne J; DeWire R; Areia D; Bryant S; Weiner S; Desai-Krieger D; Guzzie-Peck P; Evans DC; Tonelli A
    Regul Toxicol Pharmacol; 2009 Oct; 55(1):33-42. PubMed ID: 19500632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A simple method for risk assessment and its application to 1,3-butadiene].
    Zocchetti C; Pesatori AC; Bertazzi PA
    Med Lav; 2004; 95(5):392-409. PubMed ID: 15595202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of genetic toxicology information for risk assessment.
    Dearfield KL; Moore MM
    Environ Mol Mutagen; 2005 Dec; 46(4):236-45. PubMed ID: 16258925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Risk evaluation of carcinogens and their threshold levels, part III].
    Neumann HG
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Sep; 49(9):911-20. PubMed ID: 16937321
    [No Abstract]   [Full Text] [Related]  

  • 36. [A new approach to diagnosing mutagenic and carcinogenic properties of environmental factors].
    Sycheva LP; Zhurkov VS; Rakhmanin IuA
    Gig Sanit; 2003; (6):87-91. PubMed ID: 14735758
    [No Abstract]   [Full Text] [Related]  

  • 37. Antimutagens, anticarcinogens, and effective worldwide cancer prevention.
    Weisburger JH
    J Environ Pathol Toxicol Oncol; 1999; 18(2):85-93. PubMed ID: 15281219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
    Bercu JP; Hoffman WP; Lee C; Ness DK
    Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic. Preface.
    Expert Group Members
    Food Chem Toxicol; 2010 Jan; 48 Suppl 1():S1. PubMed ID: 20113849
    [No Abstract]   [Full Text] [Related]  

  • 40. [Approaches to assessing the human risk of mutagens].
    Zhurkov VS; Sycheva LP; Revazova IuA; Novikova SM
    Gig Sanit; 2006; (5):23-4. PubMed ID: 17087204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.